Free Trial

This company recently went public with an IPO on Thursday, October 15th 2026. They issued 9,375,000 shares at $15.00 - $17.00 per share. We will continue to update data for IAM as it becomes available.

Iambic Therapeutics (IAM) 10K Form and Latest SEC Filings 2026

$23.81 +4.90 (+25.91%)
As of 10/16/2026 04:00 PM Eastern

Latest Iambic Therapeutics SEC Filings & Recent Activity

Iambic Therapeutics (NASDAQ:IAM) has submitted 39+ documents to the U.S. Securities and Exchange Commission (SEC) since 2023. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. The most recent filing was a Form 8-K submitted on October 16, 2026.

Form 4
Iambic Therapeutics, Inc. Reports Ownership Change on Oct. 16, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
Iambic Therapeutics Files Current Report on Oct. 16, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

Iambic Therapeutics SEC Filing History

Browse Iambic Therapeutics' complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

Filing Date
0 Results
DateFilerForm TypeView
10/16/2026 4:03 PM
Iambic Therapeutics (1997038) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/16/2026 3:22 PM
Iambic Therapeutics (1997038) Issuer
Sharp Shalini (1377202) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/16/2026 3:24 PM
Iambic Therapeutics (1997038) Issuer
TAGLIAFERRI MARY (1323304) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/16/2026 3:26 PM
Iambic Therapeutics (1997038) Issuer
Vogelstein R Jacob (2154030) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/16/2026 3:27 PM
EMSTER KURT VON (1252524) Reporting
Iambic Therapeutics (1997038) Issuer
Form 4
Statement of changes in beneficial ownership of securities  
10/16/2026 3:09 PM
Iambic Therapeutics (1997038) Issuer
Manby Frederick R (2156015) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/16/2026 3:12 PM
Iambic Therapeutics (1997038) Issuer
Josephson Neil (1864141) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/16/2026 3:14 PM
Iambic Therapeutics (1997038) Issuer
Olson Peter A (2155824) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/16/2026 3:16 PM
Iambic Therapeutics (1997038) Issuer
Secora Michael (1855980) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/16/2026 3:19 PM
Iambic Therapeutics (1997038) Issuer
Rachlin Evan Lockwood (2151678) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/16/2026 3:21 PM
Iambic Therapeutics (1997038) Issuer
RASTETTER WILLIAM H (1205903) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/16/2026 3:07 PM
Iambic Therapeutics (1997038) Issuer
Miller Thomas F. (2034921) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
10/15/2026 3:05 PM
Iambic Therapeutics (1997038) Filer
Form 424B4
10/14/2026 6:09 PM
Iambic Therapeutics (1997038) Filer
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
10/14/2026 11:15 PM
Iambic Therapeutics (1997038) Filer
Form EFFECT
10/14/2026 7:40 PM
Catalio Access Fund VIII, LLC (2126358) Reporting
Catalio BH SPV, LLC (2158029) Reporting
Catalio Capital Management, LP (1958125) Reporting
Catalio Nexus Fund III, LP (1856688) Reporting
Iambic Therapeutics (1997038) Issuer
Petrocheilos George C (1842753) Reporting
Form 3
Initial statement of beneficial ownership of securities  
10/14/2026 5:54 PM
EMSTER KURT VON (1252524) Reporting
Iambic Therapeutics (1997038) Issuer
Form 3
Initial statement of beneficial ownership of securities  
10/14/2026 5:38 PM
Iambic Therapeutics (1997038) Issuer
Olson Peter A (2155824) Reporting
Form 3
Initial statement of beneficial ownership of securities  
10/14/2026 5:40 PM
Iambic Therapeutics (1997038) Issuer
Secora Michael (1855980) Reporting
Form 3
Initial statement of beneficial ownership of securities  
10/14/2026 5:41 PM
Hirawat Samit (1781290) Reporting
Iambic Therapeutics (1997038) Issuer
Form 3
Initial statement of beneficial ownership of securities  
10/14/2026 5:43 PM
Iambic Therapeutics (1997038) Issuer
Rachlin Evan Lockwood (2151678) Reporting
Form 3
Initial statement of beneficial ownership of securities  
10/14/2026 5:45 PM
Iambic Therapeutics (1997038) Issuer
RASTETTER WILLIAM H (1205903) Reporting
Form 3
Initial statement of beneficial ownership of securities  
10/14/2026 5:48 PM
Iambic Therapeutics (1997038) Issuer
Sharp Shalini (1377202) Reporting
Form 3
Initial statement of beneficial ownership of securities  
10/14/2026 5:50 PM
Iambic Therapeutics (1997038) Issuer
TAGLIAFERRI MARY (1323304) Reporting
Form 3
Initial statement of beneficial ownership of securities  
10/14/2026 5:51 PM
Iambic Therapeutics (1997038) Issuer
Vogelstein R Jacob (2154030) Reporting
Form 3
Initial statement of beneficial ownership of securities  
10/14/2026 5:30 PM
Iambic Therapeutics (1997038) Issuer
Miller Thomas F. (2034921) Reporting
Form 3
Initial statement of beneficial ownership of securities  
10/14/2026 5:32 PM
Iambic Therapeutics (1997038) Issuer
Manby Frederick R (2156015) Reporting
Form 3
Initial statement of beneficial ownership of securities  
10/14/2026 5:34 PM
Iambic Therapeutics (1997038) Issuer
Josephson Neil (1864141) Reporting
Form 3
Initial statement of beneficial ownership of securities  
10/14/2026 10:45 AM
Iambic Therapeutics (1997038) Filer
Form CERT
10/13/2026 3:00 PM
Iambic Therapeutics (1997038) Filer
Form 8-A12B
10/08/2026 6:09 AM
Iambic Therapeutics (1997038) Filer
Form S-1/A
09/21/2026 3:26 PM
Iambic Therapeutics (1997038) Filer
Form S-1
Registration statement under Securities Act of 1933  
09/09/2026 11:20 AM
Iambic Therapeutics (1997038) Filer
Form D
Notice of Exempt Offering of Securities 
04/08/2026 4:17 PM
Iambic Therapeutics (1997038) Filer
Form D
Notice of Exempt Offering of Securities 
11/21/2025 10:25 AM
Iambic Therapeutics (1997038) Filer
Form D
Notice of Exempt Offering of Securities 
(Data available from 1/1/2016 forward)

Iambic Therapeutics SEC Filings - Frequently Asked Questions

Iambic Therapeutics (IAM) has submitted 39+ filings to the SEC since 2023. You can browse the complete history or filter by form type using the tools above.

The most recent filing was a Form 8-K submitted on October 16, 2026. This was a current report on a material business event.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


SEC filings for NASDAQ:IAM are sourced directly from the U.S. Securities and Exchange Commission (SEC), with the most recent filing dated 10/16/2026. New filings are added as they're published.
From Our Partners